Jirong Peng

age ~62

from Mequon, WI

Also known as:
  • Peng Jirong
  • Sui Girong

Jirong Peng Phones & Addresses

  • Mequon, WI
  • Hamden, CT
  • Whitefish Bay, WI
  • Salt Lake City, UT
  • Vestavia Hills, AL
  • Rowland Heights, CA
  • Rowland Heights, CA
  • East Lansing, MI
  • 11019 N Kensington Dr, Mequon, WI 53097 • 4149855436

Us Patents

  • Cyclopentene Nucleosides, Preparation Thereof And Use As Inhibitors Of Rna Viral Polymerases

    view source
  • US Patent:
    20040242599, Dec 2, 2004
  • Filed:
    Feb 26, 2004
  • Appl. No.:
    10/786324
  • Inventors:
    Pooran Chand - Birmingham AL, US
    Yarlagadda Babu - Birmingham AL, US
    Jirong Peng - Birmingham AL, US
    Min Wu - Vestavia Hills AL, US
  • Assignee:
    BIOCRYST PHARMACEUTICALS, INC. - Birmingham AL
  • International Classification:
    A61K031/522
    A61K031/513
    C07D473/12
  • US Classification:
    514/263370, 514/263400, 514/269000, 544/276000, 544/277000, 544/309000
  • Abstract:
    Ris chosen from Calkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, H, OR, N, NRR, COR, SR, with the exception wherein Ris OH Ris selected from the group of H, halogen, N, (CH)R, Rand Rare individually chosen from the group consisting of H, OH, halogen, CN, NO, N, SR, SOR, (CH)RRand Rare selected from the group of H, OH, Halogen, CN, NO, N, SR, SOR, (CH)RX is selected from the group of H, OH, CN, NO, N, halogen Both X and (CH)Rtogether can be O, N—OH Rand Rare selected from the group of H, OR, NRR, C(O)NRR, R, R, OR, COR, C(O)R, Ris chosen from: Ris selected from the group consisting of H, F, SR, ORRis chosen from the group of H, alkyl, alkenyl, alkynyl, aryl, and hydroxyprotecting group, Rand Rare independently selected from the group of H, alkyl, alkenyl, alkynyl, and aryl Y is chosen from CH, CF, CHF, and O, Z is chosen from O, S, B is selected from the group of purine, pyrimidine and heterocycle m is 0, 1, 2, 3, or 4 and pharmaceutically acceptable salts thereof and prodrugs thereof.
  • Treatment Of Egfr Mutant-Related Cancers Using A Combination Of Egfr And Cdk4/6 Inhibitors

    view source
  • US Patent:
    20220347177, Nov 3, 2022
  • Filed:
    Sep 23, 2020
  • Appl. No.:
    17/641868
  • Inventors:
    - Wilmington DE, US
    Michael John Costanzo - Bonney Lake WA, US
    Michael Alan Green - Easton PA, US
    Don Zhang - Princeton NJ, US
    Jirong Peng - Mequon WI, US
  • International Classification:
    A61K 31/506
    A61P 35/00
    A61P 11/00
  • Abstract:
    Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatment of EGFR mutant-related cancers are disclosed:
  • Pyridopyrimidine Derivatives As Kras Inhibitors

    view source
  • US Patent:
    20230099858, Mar 30, 2023
  • Filed:
    Feb 19, 2021
  • Appl. No.:
    17/797452
  • Inventors:
    - Wilmington DE, US
    Jirong Peng - Mequon WI, US
    Michael John Costanzo - Bonney Lake WA, US
    Michael Alan Green - Easton PA, US
    Michael Nicholas Greco - Lansdale PA, US
  • International Classification:
    C07D 487/04
    C07D 519/00
  • Abstract:
    The present invention is directed to inhibitors of Kirsten Rat sacoma virus (KRAS), and more particularly to compounds of Formula (I), as well as compositions comprising Formula I and methods of using the compound of Formula I for the treatment or prevention of a disease, disorder, or medical condition mediated through KRAS, especially the KRAS mutant G12C.
  • 2H-Indazole Derivatives As Cdk4 And Cdk6 Inhibitors And Therapeutic Uses Thereof

    view source
  • US Patent:
    20210139459, May 13, 2021
  • Filed:
    Jan 29, 2019
  • Appl. No.:
    16/965376
  • Inventors:
    - Wilmington DE, US
    Michael John Costanzo - Warminster PA, US
    Jirong Peng - Mequon WI, US
    Don Zhang - Princeton NJ, US
  • International Classification:
    C07D 401/14
    A61K 45/06
  • Abstract:
    2-Aminopyrimidine-substituted 2H-indazole compounds of formula (I), where Ris hydrogen, and their prodrugs, where Ris a metabolizable group under physiological conditions, as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.
  • 2-Anilinopyrimidine Derivatives As Therapeutic Agents For Treatment Of Brain Cancers

    view source
  • US Patent:
    20190365755, Dec 5, 2019
  • Filed:
    May 11, 2017
  • Appl. No.:
    16/300949
  • Inventors:
    - Wilmington DE, US
    Michael John Costanzo - Warminster PA, US
    Michael Alan Green - Easton PA, US
    Jirong Peng - Mequon WI, US
    Victoria Lynn Wilde - Montclair NJ, US
    Don Zhang - Princeton NJ, US
  • Assignee:
    Beta Pharma, Inc. - Wilmington DE
  • International Classification:
    A61K 31/506
    A61P 35/04
  • Abstract:
    Methods of using substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, or compositions, for the treatment of brain cancers, in particular EGFR-mediated metastatic brain cancer, are disclosed.
  • Pharmaceutical Salts N-(2-(2-(Dimethylamino)Ethoxy)-4-Methoxy-5-((4-(1-Methyl-1H-Indol-3-Yl)Pyrimidin-2-Yl)Amino)Phenyl)Acrylamide And Crystalline Forms Thereof

    view source
  • US Patent:
    20190233399, Aug 1, 2019
  • Filed:
    Jun 16, 2017
  • Appl. No.:
    16/310239
  • Inventors:
    - Wilmington DE, US
    Michael J. Costanzo - Warminster PA, US
    Michael A. Green - Easton PA, US
    Jirong Peng - Mequon WI, US
    Victoria Lynn Wilde - Montclair NJ, US
    Don Zhang - Princeton NJ, US
  • Assignee:
    Beta Pharma, Inc. - Wilmington DE
  • International Classification:
    C07D 403/04
    C07C 309/30
    C07C 309/04
    A61K 45/06
    A61K 31/506
    A61P 35/00
    A61P 35/04
  • Abstract:
    Crystalline forms of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (1) and its pharmaceutically acceptable salts and compositions thereof useful for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.
  • 2-H-Indazole Derivatives As Cyclin-Dependent Kinase (Cdk) Inhibotors And Therapeutic Uses Thereof

    view source
  • US Patent:
    20180148431, May 31, 2018
  • Filed:
    Jan 29, 2018
  • Appl. No.:
    15/882620
  • Inventors:
    - Wilmington DE, US
    Michael John Costanzo - Warminster PA, US
    Jirong Peng - Mequon WI, US
    Victoria Lynn Wilde - Montclair NJ, US
    Don Zhang - Princeton NJ, US
  • Assignee:
    Beta Pharma, Inc. - Wilmington DE
  • International Classification:
    C07D 401/14
    A61K 45/06
    A61K 31/506
  • Abstract:
    Indazole compounds of formula (I) as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.
  • 2-H-Indazole Derivatives As Cyclin-Dependent Kinase (Cdk) Inhibitors And Therapeutic Uses Thereof

    view source
  • US Patent:
    20170210726, Jul 27, 2017
  • Filed:
    Jul 24, 2015
  • Appl. No.:
    15/328813
  • Inventors:
    - Wilmington DE, US
    Michael John Costanzo - Warminster PA, US
    Jirong Peng - Mequon WI, US
    Victoria Lynn Wilde - Montclair NJ, US
    Don Zhang - Plainsboro NJ, US
  • Assignee:
    Beta Pharma, Inc. - Wilmington DE
  • International Classification:
    C07D 401/14
    A61K 45/06
    A61K 31/506
  • Abstract:
    Indazole compounds of formula (I) as cyclin-dependent kinase (CDK) and cellproliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions:

Get Report for Jirong Peng from Mequon, WI, age ~62
Control profile